Skip to main content
Top
Published in: Nutrition & Metabolism 1/2014

Open Access 01-12-2014 | Research

Herbal adaptogens combined with protein fractions from bovine colostrum and hen egg yolk reduce liver TNF-α expression and protein carbonylation in Western diet feeding in rats

Authors: C Brooks Mobley, Ryan G Toedebusch, Christopher M Lockwood, Alexander J Heese, Conan Zhu, Anna E Krieger, Clayton L Cruthirds, John C Hofheins, Joseph M Company, Charles E Wiedmeyer, Dae Y Kim, Frank W Booth, Michael D Roberts

Published in: Nutrition & Metabolism | Issue 1/2014

Login to get access

Abstract

Background

We examined if a purported anti-inflammatory supplement (AF) abrogated Western-diet (WD)-induced liver pathology in rats. AF contained: 1) protein concentrates from bovine colostrum and avian egg yolk; 2) herbal adaptogens and antioxidants; and 3) acetyl-L-carnitine.

Methods

Nine month-old male Brown Norway rats were allowed ad libitum access to WD for 41–43 days and randomly assigned to WD + AF feeding twice daily for the last 31–33 days (n = 8), or WD and water-placebo feeding twice daily for the last 31–33 days (n = 8). Rats fed a low-fat/low-sucrose diet (CTL, n = 6) for 41–43 days and administered a water-placebo twice daily for the last 31–33 days were also studied. Twenty-four hours following the last gavage-feed, liver samples were analyzed for: a) select mRNAs (via RT-PCR) as well as genome-wide mRNA expression patterns (via RNA-seq); b) lipid deposition; and, c) protein carbonyl and total antioxidant capacity (TAC). Serum was also examined for TAC, 8-isoprostane and clinical chemistry markers.

Results

WD + AF rats experienced a reduction in liver Tnf-α mRNA (-2.8-fold, p < 0.01). Serum and liver TAC was lower in WD + AF versus WD and CTL rats (p < 0.05), likely due to exogenous antioxidant ingredients provided through AF as evidenced by a tendency for mitochondrial SOD2 mRNA to increase in WD + AF versus CTL rats (p = 0.07). Liver fat deposition nor liver protein carbonyl content differed between WD + AF versus WD rats, although liver protein carbonyls tended to be lower in WD + AF versus CTL rats (p = 0.08). RNA-seq revealed that 19 liver mRNAs differed between WD + AF versus WD when both groups were compared with CTL rats (+/- 1.5-fold, p < 0.01). Bioinformatics suggest that AF prevented WD-induced alterations in select genes related to the transport and metabolism of carbohydrates in favor of select genes related to lipid transport and metabolism. Finally, serum clinical safety markers and liver pathology (via lesion counting) suggests that chronic consumption of AF was well tolerated.

Conclusions

AF supplementation elicits select metabolic, anti-inflammatory, and anti-oxidant properties which was in spite of WD feeding and persisted up to 24 hours after receiving a final dose.
Appendix
Available only for authorised users
Literature
1.
go back to reference Tessari P, Coracina A, Cosma A, Tiengo A: Hepatic lipid metabolism and non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2009, 19: 291-302. 10.1016/j.numecd.2008.12.015.CrossRef Tessari P, Coracina A, Cosma A, Tiengo A: Hepatic lipid metabolism and non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2009, 19: 291-302. 10.1016/j.numecd.2008.12.015.CrossRef
2.
go back to reference De Vito R, Alisi A, Masotti A, Ceccarelli S, Panera N, Citti A, Salata M, Valenti L, Feldstein AE, Nobili V: Markers of activated inflammatory cells correlate with severity of liver damage in children with nonalcoholic fatty liver disease. Int J Mol Med. 2012, 30: 49-56. De Vito R, Alisi A, Masotti A, Ceccarelli S, Panera N, Citti A, Salata M, Valenti L, Feldstein AE, Nobili V: Markers of activated inflammatory cells correlate with severity of liver damage in children with nonalcoholic fatty liver disease. Int J Mol Med. 2012, 30: 49-56.
3.
go back to reference Rahimi RS, Landaverde C: Nonalcoholic fatty liver disease and the metabolic syndrome: clinical implications and treatment. Nutr Clin Pract. 2013, 28: 40-51. 10.1177/0884533612470464.CrossRef Rahimi RS, Landaverde C: Nonalcoholic fatty liver disease and the metabolic syndrome: clinical implications and treatment. Nutr Clin Pract. 2013, 28: 40-51. 10.1177/0884533612470464.CrossRef
4.
go back to reference de Wit NJ, Afman LA, Mensink M, Muller M: Phenotyping the effect of diet on non-alcoholic fatty liver disease. J Hepatol. 2012, 57: 1370-1373. 10.1016/j.jhep.2012.07.003.CrossRef de Wit NJ, Afman LA, Mensink M, Muller M: Phenotyping the effect of diet on non-alcoholic fatty liver disease. J Hepatol. 2012, 57: 1370-1373. 10.1016/j.jhep.2012.07.003.CrossRef
5.
6.
go back to reference Byrne CD, Olufadi R, Bruce KD, Cagampang FR, Ahmed MH: Metabolic disturbances in non-alcoholic fatty liver disease. Clin Sci. 2009, 116: 539-564. 10.1042/CS20080253.CrossRef Byrne CD, Olufadi R, Bruce KD, Cagampang FR, Ahmed MH: Metabolic disturbances in non-alcoholic fatty liver disease. Clin Sci. 2009, 116: 539-564. 10.1042/CS20080253.CrossRef
7.
go back to reference Schuppan D, Schattenberg JM: Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches. J Gastroenterol Hepatol. 2013, 28 (Suppl 1): 68-76.CrossRef Schuppan D, Schattenberg JM: Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches. J Gastroenterol Hepatol. 2013, 28 (Suppl 1): 68-76.CrossRef
8.
go back to reference Centis E, Marzocchi R, Di Domizio S, Ciaravella MF, Marchesini G: The effect of lifestyle changes in non-alcoholic fatty liver disease. Dig Dis. 2010, 28: 267-273. 10.1159/000282101.CrossRef Centis E, Marzocchi R, Di Domizio S, Ciaravella MF, Marchesini G: The effect of lifestyle changes in non-alcoholic fatty liver disease. Dig Dis. 2010, 28: 267-273. 10.1159/000282101.CrossRef
9.
go back to reference Fromenty B, Robin MA, Igoudjil A, Mansouri A, Pessayre D: The ins and outs of mitochondrial dysfunction in NASH. Diabetes Metabol. 2004, 30: 121-138. 10.1016/S1262-3636(07)70098-8.CrossRef Fromenty B, Robin MA, Igoudjil A, Mansouri A, Pessayre D: The ins and outs of mitochondrial dysfunction in NASH. Diabetes Metabol. 2004, 30: 121-138. 10.1016/S1262-3636(07)70098-8.CrossRef
10.
go back to reference Ishimoto T, Lanaspa MA, Rivard CJ, Roncal-Jimenez CA, Orlicky DJ, Cicerchi C, McMahan RH, Abdelmalek MF, Rosen HR, Jackman MR, MacLean PS, Diggle CP, Asipu A, Inaba S, Kosugi T, Sato W, Maruyama S, Sánchez-Lozada LG, Sautin YY, Hill JO, Bonthron DT, Johnson RJ: High fat and high sucrose (western) diet induce steatohepatitis that is dependent on fructokinase. Hepatology. 2013, 58: 1632-1643. 10.1002/hep.26594.CrossRef Ishimoto T, Lanaspa MA, Rivard CJ, Roncal-Jimenez CA, Orlicky DJ, Cicerchi C, McMahan RH, Abdelmalek MF, Rosen HR, Jackman MR, MacLean PS, Diggle CP, Asipu A, Inaba S, Kosugi T, Sato W, Maruyama S, Sánchez-Lozada LG, Sautin YY, Hill JO, Bonthron DT, Johnson RJ: High fat and high sucrose (western) diet induce steatohepatitis that is dependent on fructokinase. Hepatology. 2013, 58: 1632-1643. 10.1002/hep.26594.CrossRef
11.
go back to reference Zelber-Sagi S, Ratziu V, Oren R: Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. World J Gastroenterol. 2011, 17: 3377-3389. 10.3748/wjg.v17.i29.3377.CrossRef Zelber-Sagi S, Ratziu V, Oren R: Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. World J Gastroenterol. 2011, 17: 3377-3389. 10.3748/wjg.v17.i29.3377.CrossRef
12.
go back to reference Kashi MR, Torres DM, Harrison SA: Current and emerging therapies in nonalcoholic fatty liver disease. Semin Liver Dis. 2008, 28: 396-406. 10.1055/s-0028-1091984.CrossRef Kashi MR, Torres DM, Harrison SA: Current and emerging therapies in nonalcoholic fatty liver disease. Semin Liver Dis. 2008, 28: 396-406. 10.1055/s-0028-1091984.CrossRef
13.
go back to reference Bugianesi E, Marzocchi R, Villanova N, Marchesini G: Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment. Best Pract Res Clin Gastroenterol. 2004, 18: 1105-1116. 10.1016/j.bpg.2004.06.025.CrossRef Bugianesi E, Marzocchi R, Villanova N, Marchesini G: Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment. Best Pract Res Clin Gastroenterol. 2004, 18: 1105-1116. 10.1016/j.bpg.2004.06.025.CrossRef
14.
go back to reference Al-Busafi SA, Bhat M, Wong P, Ghali P, Deschenes M: Antioxidant therapy in nonalcoholic steatohepatitis. Hepatitis Research and Treatment. 2012, 2012: 947575-CrossRef Al-Busafi SA, Bhat M, Wong P, Ghali P, Deschenes M: Antioxidant therapy in nonalcoholic steatohepatitis. Hepatitis Research and Treatment. 2012, 2012: 947575-CrossRef
15.
go back to reference Lirussi F, Azzalini L, Orando S, Orlando R, Angelico F: Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev. 2007, 1: CD004996- Lirussi F, Azzalini L, Orando S, Orlando R, Angelico F: Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev. 2007, 1: CD004996-
16.
go back to reference Przybylska J, Albera E, Kankofer M: Antioxidants in bovine colostrum. Reprod Domest Anim. 2007, 42: 402-409. 10.1111/j.1439-0531.2006.00799.x.CrossRef Przybylska J, Albera E, Kankofer M: Antioxidants in bovine colostrum. Reprod Domest Anim. 2007, 42: 402-409. 10.1111/j.1439-0531.2006.00799.x.CrossRef
17.
go back to reference Mehta K, Van Thiel DH, Shah N, Mobarhan S: Nonalcoholic fatty liver disease: pathogenesis and the role of antioxidants. Nutr Rev. 2002, 60: 289-293. 10.1301/002966402320387224.CrossRef Mehta K, Van Thiel DH, Shah N, Mobarhan S: Nonalcoholic fatty liver disease: pathogenesis and the role of antioxidants. Nutr Rev. 2002, 60: 289-293. 10.1301/002966402320387224.CrossRef
18.
go back to reference Chitturi S, Farrell GC: Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis. 2001, 21: 27-41. 10.1055/s-2001-12927.CrossRef Chitturi S, Farrell GC: Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis. 2001, 21: 27-41. 10.1055/s-2001-12927.CrossRef
19.
go back to reference McCullough AJ: Update on nonalcoholic fatty liver disease. J Clin Gastroenterol. 2002, 34: 255-262. 10.1097/00004836-200203000-00013.CrossRef McCullough AJ: Update on nonalcoholic fatty liver disease. J Clin Gastroenterol. 2002, 34: 255-262. 10.1097/00004836-200203000-00013.CrossRef
20.
go back to reference Matsunami T, Sato Y, Ariga S, Sato T, Kashimura H, Hasegawa Y, Yukawa M: Regulation of oxidative stress and inflammation by hepatic adiponectin receptor 2 in an animal model of nonalcoholic steatohepatitis. Int J Clin Exp Pathol. 2010, 3: 472-481. Matsunami T, Sato Y, Ariga S, Sato T, Kashimura H, Hasegawa Y, Yukawa M: Regulation of oxidative stress and inflammation by hepatic adiponectin receptor 2 in an animal model of nonalcoholic steatohepatitis. Int J Clin Exp Pathol. 2010, 3: 472-481.
21.
go back to reference Park HJ, DiNatale DA, Chung MY, Park YK, Lee JY, Koo SI, O’Connor M, Manautou JE, Bruno RS: Green tea extract attenuates hepatic steatosis by decreasing adipose lipogenesis and enhancing hepatic antioxidant defenses in ob/ob mice. J Nutr Biochem. 2011, 22: 393-400. 10.1016/j.jnutbio.2010.03.009.CrossRef Park HJ, DiNatale DA, Chung MY, Park YK, Lee JY, Koo SI, O’Connor M, Manautou JE, Bruno RS: Green tea extract attenuates hepatic steatosis by decreasing adipose lipogenesis and enhancing hepatic antioxidant defenses in ob/ob mice. J Nutr Biochem. 2011, 22: 393-400. 10.1016/j.jnutbio.2010.03.009.CrossRef
22.
go back to reference Park HJ, Lee JY, Chung MY, Park YK, Bower AM, Koo SI, Giardina C, Bruno RS: Green tea extract suppresses NFkappaB activation and inflammatory responses in diet-induced obese rats with nonalcoholic steatohepatitis. J Nutr. 2012, 142: 57-63. 10.3945/jn.111.148544.CrossRef Park HJ, Lee JY, Chung MY, Park YK, Bower AM, Koo SI, Giardina C, Bruno RS: Green tea extract suppresses NFkappaB activation and inflammatory responses in diet-induced obese rats with nonalcoholic steatohepatitis. J Nutr. 2012, 142: 57-63. 10.3945/jn.111.148544.CrossRef
23.
go back to reference Li L, Hai J, Li Z, Zhang Y, Peng H, Li K, Weng X: Resveratrol modulates autophagy and NF-kappaB activity in a murine model for treating non-alcoholic fatty liver disease. Food Chem Toxicol. 2013, 63: 166-173.CrossRef Li L, Hai J, Li Z, Zhang Y, Peng H, Li K, Weng X: Resveratrol modulates autophagy and NF-kappaB activity in a murine model for treating non-alcoholic fatty liver disease. Food Chem Toxicol. 2013, 63: 166-173.CrossRef
24.
go back to reference Rivera L, Moron R, Zarzuelo A, Galisteo M: Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem Pharmacol. 2009, 77: 1053-1063. 10.1016/j.bcp.2008.11.027.CrossRef Rivera L, Moron R, Zarzuelo A, Galisteo M: Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem Pharmacol. 2009, 77: 1053-1063. 10.1016/j.bcp.2008.11.027.CrossRef
25.
go back to reference Rubiolo JA, Mithieux G, Vega FV: Resveratrol protects primary rat hepatocytes against oxidative stress damage: activation of the Nrf2 transcription factor and augmented activities of antioxidant enzymes. Eur J Pharmacol. 2008, 591: 66-72. 10.1016/j.ejphar.2008.06.067.CrossRef Rubiolo JA, Mithieux G, Vega FV: Resveratrol protects primary rat hepatocytes against oxidative stress damage: activation of the Nrf2 transcription factor and augmented activities of antioxidant enzymes. Eur J Pharmacol. 2008, 591: 66-72. 10.1016/j.ejphar.2008.06.067.CrossRef
26.
go back to reference Chung MY, Park HJ, Manautou JE, Koo SI, Bruno RS: Green tea extract protects against nonalcoholic steatohepatitis in ob/ob mice by decreasing oxidative and nitrative stress responses induced by proinflammatory enzymes. J Nutr Biochem. 2012, 23: 361-367. 10.1016/j.jnutbio.2011.01.001.CrossRef Chung MY, Park HJ, Manautou JE, Koo SI, Bruno RS: Green tea extract protects against nonalcoholic steatohepatitis in ob/ob mice by decreasing oxidative and nitrative stress responses induced by proinflammatory enzymes. J Nutr Biochem. 2012, 23: 361-367. 10.1016/j.jnutbio.2011.01.001.CrossRef
27.
go back to reference Gomez-Zorita S, Fernandez-Quintela A, Macarulla MT, Aguirre L, Hijona E, Bujanda L, Milagro F, Martinez JA, Portillo MP: Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress. Br J Nutr. 2012, 107: 202-210. 10.1017/S0007114511002753.CrossRef Gomez-Zorita S, Fernandez-Quintela A, Macarulla MT, Aguirre L, Hijona E, Bujanda L, Milagro F, Martinez JA, Portillo MP: Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress. Br J Nutr. 2012, 107: 202-210. 10.1017/S0007114511002753.CrossRef
28.
go back to reference Jwa H, Choi Y, Park UH, Um SJ, Yoon SK, Park T: Piperine, an LXRalpha antagonist, protects against hepatic steatosis and improves insulin signaling in mice fed a high-fat diet. Biochem Pharmacol. 2012, 84: 1501-1510. 10.1016/j.bcp.2012.09.009.CrossRef Jwa H, Choi Y, Park UH, Um SJ, Yoon SK, Park T: Piperine, an LXRalpha antagonist, protects against hepatic steatosis and improves insulin signaling in mice fed a high-fat diet. Biochem Pharmacol. 2012, 84: 1501-1510. 10.1016/j.bcp.2012.09.009.CrossRef
29.
go back to reference Nagao K, Jinnouchi T, Kai S, Yanagita T: Effect of dietary resveratrol on the metabolic profile of nutrients in obese OLETF rats. Lipids Health Dis. 2013, 12: 8-10.1186/1476-511X-12-8.CrossRef Nagao K, Jinnouchi T, Kai S, Yanagita T: Effect of dietary resveratrol on the metabolic profile of nutrients in obese OLETF rats. Lipids Health Dis. 2013, 12: 8-10.1186/1476-511X-12-8.CrossRef
30.
go back to reference Reagan-Shaw S, Nihal M, Ahmad N: Dose translation from animal to human studies revisited. FASEB J. 2008, 22: 659-661.CrossRef Reagan-Shaw S, Nihal M, Ahmad N: Dose translation from animal to human studies revisited. FASEB J. 2008, 22: 659-661.CrossRef
31.
go back to reference VanSaun MN, Lee IK, Washington MK, Matrisian L, Gorden DL: High fat diet induced hepatic steatosis establishes a permissive microenvironment for colorectal metastases and promotes primary dysplasia in a murine model. Am J Pathol. 2009, 175: 355-364. 10.2353/ajpath.2009.080703.CrossRef VanSaun MN, Lee IK, Washington MK, Matrisian L, Gorden DL: High fat diet induced hepatic steatosis establishes a permissive microenvironment for colorectal metastases and promotes primary dysplasia in a murine model. Am J Pathol. 2009, 175: 355-364. 10.2353/ajpath.2009.080703.CrossRef
32.
go back to reference Li ZZ, Berk M, McIntyre TM, Feldstein AE: Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase. J Biol Chem. 2009, 284: 5637-5644. 10.1074/jbc.M807616200.CrossRef Li ZZ, Berk M, McIntyre TM, Feldstein AE: Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase. J Biol Chem. 2009, 284: 5637-5644. 10.1074/jbc.M807616200.CrossRef
33.
go back to reference Toedebusch RG, Childs TE, Hamilton SR, Crowley JR, Booth FW, Roberts MD: Postprandial leucine and insulin responses and toxicological effects of a novel whey protein hydrolysate-based supplement in rats. J Int Soc Sports Nutr. 2012, 9: 24-10.1186/1550-2783-9-24.CrossRef Toedebusch RG, Childs TE, Hamilton SR, Crowley JR, Booth FW, Roberts MD: Postprandial leucine and insulin responses and toxicological effects of a novel whey protein hydrolysate-based supplement in rats. J Int Soc Sports Nutr. 2012, 9: 24-10.1186/1550-2783-9-24.CrossRef
34.
go back to reference Rustemeyer SM, Lamberson WR, Ledoux DR, Wells K, Austin KJ, Cammack KM: Effects of dietary aflatoxin on the hepatic expression of apoptosis genes in growing barrows. J Anim Sci. 2011, 89: 916-925. 10.2527/jas.2010-3473.CrossRef Rustemeyer SM, Lamberson WR, Ledoux DR, Wells K, Austin KJ, Cammack KM: Effects of dietary aflatoxin on the hepatic expression of apoptosis genes in growing barrows. J Anim Sci. 2011, 89: 916-925. 10.2527/jas.2010-3473.CrossRef
35.
go back to reference Song HK, Hong SE, Kim T, Kim Do H: Deep RNA sequencing reveals novel cardiac transcriptomic signatures for physiological and pathological hypertrophy. PLoS One. 2012, 7: e35552-10.1371/journal.pone.0035552.CrossRef Song HK, Hong SE, Kim T, Kim Do H: Deep RNA sequencing reveals novel cardiac transcriptomic signatures for physiological and pathological hypertrophy. PLoS One. 2012, 7: e35552-10.1371/journal.pone.0035552.CrossRef
36.
go back to reference Zhang LQ, Cheranova D, Gibson M, Ding S, Heruth DP, Fang D, Ye SQ: RNA-seq reveals novel transcriptome of genes and their isoforms in human pulmonary microvascular endothelial cells treated with thrombin. PLoS One. 2012, 7: e31229-10.1371/journal.pone.0031229.CrossRef Zhang LQ, Cheranova D, Gibson M, Ding S, Heruth DP, Fang D, Ye SQ: RNA-seq reveals novel transcriptome of genes and their isoforms in human pulmonary microvascular endothelial cells treated with thrombin. PLoS One. 2012, 7: e31229-10.1371/journal.pone.0031229.CrossRef
37.
go back to reference Heruth DP, Gibson M, Grigoryev DN, Zhang LQ, Ye SQ: RNA-seq analysis of synovial fibroblasts brings new insights into rheumatoid arthritis. Cell Biosci. 2012, 2: 43-10.1186/2045-3701-2-43.CrossRef Heruth DP, Gibson M, Grigoryev DN, Zhang LQ, Ye SQ: RNA-seq analysis of synovial fibroblasts brings new insights into rheumatoid arthritis. Cell Biosci. 2012, 2: 43-10.1186/2045-3701-2-43.CrossRef
38.
go back to reference Amin A, Mahmoud-Ghoneim D: Texture analysis of liver fibrosis microscopic images: a study on the effect of biomarkers. Acta Biochim Biophys Sin. 2011, 43: 193-203. 10.1093/abbs/gmq129.CrossRef Amin A, Mahmoud-Ghoneim D: Texture analysis of liver fibrosis microscopic images: a study on the effect of biomarkers. Acta Biochim Biophys Sin. 2011, 43: 193-203. 10.1093/abbs/gmq129.CrossRef
39.
go back to reference Chen H, Sohn J, Zhang L, Tian J, Chen S, Bjeldanes LF: Anti-inflammatory effects of chicanine on murine macrophage by down-regulating LPS-induced inflammatory cytokines in IkappaBalpha/MAPK/ERK signaling pathways. Eur J Pharmacol. 2013, 724C: 168-174. Chen H, Sohn J, Zhang L, Tian J, Chen S, Bjeldanes LF: Anti-inflammatory effects of chicanine on murine macrophage by down-regulating LPS-induced inflammatory cytokines in IkappaBalpha/MAPK/ERK signaling pathways. Eur J Pharmacol. 2013, 724C: 168-174.
40.
go back to reference Dushkin M, Khrapova M, Kovshik G, Chasovskikh M, Menshchikova E, Trufakin V, Shurlygina A, Vereschagin E: Effects of rhaponticum carthamoides versus glycyrrhiza glabra and punica granatum extracts on metabolic syndrome signs in rats. BMC Complement Altern Med. 2014, 14: 33-10.1186/1472-6882-14-33.CrossRef Dushkin M, Khrapova M, Kovshik G, Chasovskikh M, Menshchikova E, Trufakin V, Shurlygina A, Vereschagin E: Effects of rhaponticum carthamoides versus glycyrrhiza glabra and punica granatum extracts on metabolic syndrome signs in rats. BMC Complement Altern Med. 2014, 14: 33-10.1186/1472-6882-14-33.CrossRef
41.
go back to reference Valtuena S, Pellegrini N, Franzini L, Bianchi MA, Ardigo D, Del Rio D, Piatti P, Scazzina F, Zavaroni I, Brighenti F: Food selection based on total antioxidant capacity can modify antioxidant intake, systemic inflammation, and liver function without altering markers of oxidative stress. Am J Clin Nutr. 2008, 87: 1290-1297. Valtuena S, Pellegrini N, Franzini L, Bianchi MA, Ardigo D, Del Rio D, Piatti P, Scazzina F, Zavaroni I, Brighenti F: Food selection based on total antioxidant capacity can modify antioxidant intake, systemic inflammation, and liver function without altering markers of oxidative stress. Am J Clin Nutr. 2008, 87: 1290-1297.
42.
go back to reference Paiva SA, Yeum KJ, Cao G, Prior RL, Russell RM: Postprandial plasma carotenoid responses following consumption of strawberries, red wine, vitamin C or spinach by elderly women. J Nutr. 1998, 128: 2391-2394. Paiva SA, Yeum KJ, Cao G, Prior RL, Russell RM: Postprandial plasma carotenoid responses following consumption of strawberries, red wine, vitamin C or spinach by elderly women. J Nutr. 1998, 128: 2391-2394.
43.
go back to reference Gomez-Cabrera MC, Ristow M, Vina J: Antioxidant supplements in exercise: worse than useless?. Am J Physiol Endocrinol Metab. 2012, 302: E476-E477. 10.1152/ajpendo.00567.2011. author reply E478–479CrossRef Gomez-Cabrera MC, Ristow M, Vina J: Antioxidant supplements in exercise: worse than useless?. Am J Physiol Endocrinol Metab. 2012, 302: E476-E477. 10.1152/ajpendo.00567.2011. author reply E478–479CrossRef
44.
go back to reference Gomez-Cabrera MC, Domenech E, Romagnoli M, Arduini A, Borras C, Pallardo FV, Sastre J, Vina J: Oral administration of vitamin C decreases muscle mitochondrial biogenesis and hampers training-induced adaptations in endurance performance. Am J Clin Nutr. 2008, 87: 142-149. Gomez-Cabrera MC, Domenech E, Romagnoli M, Arduini A, Borras C, Pallardo FV, Sastre J, Vina J: Oral administration of vitamin C decreases muscle mitochondrial biogenesis and hampers training-induced adaptations in endurance performance. Am J Clin Nutr. 2008, 87: 142-149.
45.
go back to reference Pan SY, Yu Q, Zhang Y, Wang XY, Sun N, Yu ZL, Ko KM: Dietary Fructus Schisandrae extracts and fenofibrate regulate the serum/hepatic lipid-profile in normal and hypercholesterolemic mice, with attention to hepatotoxicity. Lipids Health Dis. 2012, 11: 120-10.1186/1476-511X-11-120.CrossRef Pan SY, Yu Q, Zhang Y, Wang XY, Sun N, Yu ZL, Ko KM: Dietary Fructus Schisandrae extracts and fenofibrate regulate the serum/hepatic lipid-profile in normal and hypercholesterolemic mice, with attention to hepatotoxicity. Lipids Health Dis. 2012, 11: 120-10.1186/1476-511X-11-120.CrossRef
46.
go back to reference Gomez-Valades AG, Mendez-Lucas A, Vidal-Alabro A, Blasco FX, Chillon M, Bartrons R, Bermudez J, Perales JC: Pck1 gene silencing in the liver improves glycemia control, insulin sensitivity, and dyslipidemia in db/db mice. Diabetes. 2008, 57: 2199-2210. 10.2337/db07-1087.CrossRef Gomez-Valades AG, Mendez-Lucas A, Vidal-Alabro A, Blasco FX, Chillon M, Bartrons R, Bermudez J, Perales JC: Pck1 gene silencing in the liver improves glycemia control, insulin sensitivity, and dyslipidemia in db/db mice. Diabetes. 2008, 57: 2199-2210. 10.2337/db07-1087.CrossRef
47.
go back to reference Okamoto Y, Tanaka S, Haga Y: Enhanced GLUT2 gene expression in an oleic acid-induced in vitro fatty liver model. Hepatol Res. 2002, 23: 138-144. 10.1016/S1386-6346(01)00172-3.CrossRef Okamoto Y, Tanaka S, Haga Y: Enhanced GLUT2 gene expression in an oleic acid-induced in vitro fatty liver model. Hepatol Res. 2002, 23: 138-144. 10.1016/S1386-6346(01)00172-3.CrossRef
48.
go back to reference Love-Gregory L, Abumrad NA: CD36 genetics and the metabolic complications of obesity. Curr Opin Clin Nutr Metab Care. 2011, 14: 527-534. 10.1097/MCO.0b013e32834bbac9.CrossRef Love-Gregory L, Abumrad NA: CD36 genetics and the metabolic complications of obesity. Curr Opin Clin Nutr Metab Care. 2011, 14: 527-534. 10.1097/MCO.0b013e32834bbac9.CrossRef
49.
go back to reference Hajri T, Han XX, Bonen A, Abumrad NA: Defective fatty acid uptake modulates insulin responsiveness and metabolic responses to diet in CD36-null mice. J Clin Invest. 2002, 109: 1381-1389. 10.1172/JCI0214596.CrossRef Hajri T, Han XX, Bonen A, Abumrad NA: Defective fatty acid uptake modulates insulin responsiveness and metabolic responses to diet in CD36-null mice. J Clin Invest. 2002, 109: 1381-1389. 10.1172/JCI0214596.CrossRef
50.
go back to reference Goudriaan JR, Dahlmans VE, Teusink B, Ouwens DM, Febbraio M, Maassen JA, Romijn JA, Havekes LM, Voshol PJ: CD36 deficiency increases insulin sensitivity in muscle, but induces insulin resistance in the liver in mice. J Lipid Res. 2003, 44: 2270-2277. 10.1194/jlr.M300143-JLR200.CrossRef Goudriaan JR, Dahlmans VE, Teusink B, Ouwens DM, Febbraio M, Maassen JA, Romijn JA, Havekes LM, Voshol PJ: CD36 deficiency increases insulin sensitivity in muscle, but induces insulin resistance in the liver in mice. J Lipid Res. 2003, 44: 2270-2277. 10.1194/jlr.M300143-JLR200.CrossRef
51.
go back to reference Héron-Milhavet L, Haluzik M, Yakar S, Gavrilova O, Pack S, Jou WC, Ibrahimi A, Kim H, Hunt D, Yau D, Asghar Z, Joseph J, Wheeler MB, Abumrad NA, LeRoith D: Muscle-specific overexpression of CD36 reverses the insulin resistance and diabetes of MKR mice. Endocrinology. 2004, 145: 4667-4676. 10.1210/en.2003-1543.CrossRef Héron-Milhavet L, Haluzik M, Yakar S, Gavrilova O, Pack S, Jou WC, Ibrahimi A, Kim H, Hunt D, Yau D, Asghar Z, Joseph J, Wheeler MB, Abumrad NA, LeRoith D: Muscle-specific overexpression of CD36 reverses the insulin resistance and diabetes of MKR mice. Endocrinology. 2004, 145: 4667-4676. 10.1210/en.2003-1543.CrossRef
52.
go back to reference Wei C, Li J, Bumgarner RE: Sample size for detecting differentially expressed genes in microarray experiments. BMC Genomics. 2004, 5: 87-10.1186/1471-2164-5-87.CrossRef Wei C, Li J, Bumgarner RE: Sample size for detecting differentially expressed genes in microarray experiments. BMC Genomics. 2004, 5: 87-10.1186/1471-2164-5-87.CrossRef
53.
go back to reference Rivera L, Moron R, Sanchez M, Zarzuelo A, Galisteo M: Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese Zucker rats. Obesity (Silver Spring). 2008, 16: 2081-2087. 10.1038/oby.2008.315.CrossRef Rivera L, Moron R, Sanchez M, Zarzuelo A, Galisteo M: Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese Zucker rats. Obesity (Silver Spring). 2008, 16: 2081-2087. 10.1038/oby.2008.315.CrossRef
Metadata
Title
Herbal adaptogens combined with protein fractions from bovine colostrum and hen egg yolk reduce liver TNF-α expression and protein carbonylation in Western diet feeding in rats
Authors
C Brooks Mobley
Ryan G Toedebusch
Christopher M Lockwood
Alexander J Heese
Conan Zhu
Anna E Krieger
Clayton L Cruthirds
John C Hofheins
Joseph M Company
Charles E Wiedmeyer
Dae Y Kim
Frank W Booth
Michael D Roberts
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Nutrition & Metabolism / Issue 1/2014
Electronic ISSN: 1743-7075
DOI
https://doi.org/10.1186/1743-7075-11-19

Other articles of this Issue 1/2014

Nutrition & Metabolism 1/2014 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.